Tag: Nasdaq:AMRN
Amarin to Present at Two Investor Conferences in June 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., May 18, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero,...
REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid...
Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new...
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines...
VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication1,2,3 VAZKEPA authorization for Great Britain follows...
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in...
Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy Effect...
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent...
Reimbursement dossiers for first 10 countries to be filed in coming months 150 people hired and on-track to be deployed by mid-Q2...
Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular...
Marks first and only EC-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and other...